Distribution and characteristics of COPD phenotypes – results from the Polish sub-cohort of the POPE study
Authors Kania A, Krenke R, Kuziemski K, Czajkowska-Malinowska M, Celejewska-WĂłjcik N, KuĹşnar-KamiĹ„ska B, Farnik M, Bokiej J, Miszczuk M, Damps-KonstaĹ„ska I, Grabicki M, Trzaska-Sobczak M, SĹ‚adek K, Batura-Gabryel H, Barczyk A
Received 21 October 2017
Accepted for publication 4 March 2018
Published 17 May 2018 Volume 2018:13 Pages 1613—1621
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Charles Downs
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Aleksander Kania,1 RafaĹ‚ Krenke,2 Krzysztof Kuziemski,3 MaĹ‚gorzata Czajkowska-Malinowska,4 Natalia Celejewska-Wójcik,1 Barbara KuĹşnar-KamiĹ„ska,5 MaĹ‚gorzata Farnik,6 Juliusz Bokiej,7 Marta Miszczuk,2 Iwona Damps-KonstaĹ„ska,3 Marcin Grabicki,5 Marzena Trzaska-Sobczak,6 Krzysztof SĹ‚adek,1 Halina Batura-Gabryel,5 Adam Barczyk6
1Department of Pulmonology, II Chair of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland; 2Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland; 3Department of Allergology and Pneumonology, Medical University of GdaĹ„sk, GdaĹ„sk, Poland; 4Department of Lung Diseases and Respiratory Failure, Regional Center of Pulmonology, Bydgoszcz, Poland; 5Department of Pulmonology, Allergology and Respiratory Oncology, PoznaĹ„ University of Medical Sciences, PoznaĹ„, Poland; 6Department of Pneumology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland; 7Department of Lung Diseases, Regional Hospital Center Jelenia Góra, Jelenia Góra, Poland
Background: This study aimed to examine the distribution of predefined phenotypes, demographic data, clinical outcomes, and treatment of patients who were included in the Polish cohort of the Phenotypes of COPD in Central and Eastern Europe (POPE) study.
Patients and methods: This was a sub-analysis of the data from the Polish cohort of the POPE study, an international, multicenter, observational cross-sectional survey of COPD patients in Central and Eastern European countries. The study included patients aged .40 years, with a confirmed diagnosis of COPD, and absence of exacerbation for at least 4 weeks before study inclusion. A total of seven Polish centers participated in the study.
Results: Among the 430 Polish COPD patients enrolled in the study, 61.6% were non-exacerbators (NON-AE), 25.3% were frequent exacerbators with chronic bronchitis (AE CB), 7.9% were frequent exacerbators without chronic bronchitis (AE NON-CB), and 5.1% met the definition of asthma-COPD overlap syndrome (ACOS). There were statistically significant differences among these phenotypes in terms of symptom load, lung function, comorbidities, and treatment. Patients with the AE CB phenotype were most symptomatic with worse lung function, and more frequently reported anxiety and depression. Patients with the ACOS phenotype were significantly younger and were diagnosed with COPD earlier than those with other COPD phenotypes; those with the ACOS phenotype were also more often atopic and obese.
Conclusion: There is significant heterogeneity among COPD patients in the Polish population in terms of phenotype and clinical outcome. The non-exacerbator phenotype is observed most frequently in Poland, while the frequent exacerbator with chronic bronchitis phenotype is the most symptomatic.
Keywords: chronic obstructive pulmonary disease, asthma-COPD overlap syndrome, phenotypes
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]